Pacira BioSciences (NASDAQ:PCRX) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Pacira BioSciences (NASDAQ:PCRX) had its price objective increased by analysts at Needham & Company LLC from $22.00 to $30.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target suggests a potential upside of 45.99% from the stock’s previous close.

A number of other research firms have also issued reports on PCRX. HC Wainwright reaffirmed a “buy” rating and issued a $39.00 price target on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Barclays decreased their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. Jefferies Financial Group increased their price objective on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Finally, Royal Bank of Canada lifted their price objective on shares of Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Pacira BioSciences presently has an average rating of “Hold” and a consensus target price of $24.50.

Pacira BioSciences Stock Down 2.7 %

Shares of NASDAQ PCRX opened at $20.55 on Monday. The stock has a market cap of $948.86 million, a P/E ratio of -10.12 and a beta of 0.76. The business’s fifty day simple moving average is $18.43 and its 200-day simple moving average is $17.49. Pacira BioSciences has a 12-month low of $11.16 and a 12-month high of $34.01. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.

Hedge Funds Weigh In On Pacira BioSciences

Large investors have recently bought and sold shares of the stock. Rhumbline Advisers increased its position in shares of Pacira BioSciences by 6.6% during the second quarter. Rhumbline Advisers now owns 159,467 shares of the company’s stock worth $4,562,000 after purchasing an additional 9,869 shares in the last quarter. Victory Capital Management Inc. increased its position in Pacira BioSciences by 18.7% during the second quarter. Victory Capital Management Inc. now owns 87,639 shares of the company’s stock worth $2,507,000 after buying an additional 13,776 shares during the period. Quest Partners LLC purchased a new stake in Pacira BioSciences in the second quarter valued at approximately $113,000. American Century Companies Inc. boosted its holdings in shares of Pacira BioSciences by 16.6% in the second quarter. American Century Companies Inc. now owns 69,498 shares of the company’s stock valued at $1,988,000 after acquiring an additional 9,911 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Pacira BioSciences by 12.2% during the second quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company’s stock worth $52,300,000 after acquiring an additional 198,936 shares during the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.